
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9000370/publications.pdf

Version: 2024-02-01



IOHN I DOWEDS

#	Article	IF	CITATIONS
1	TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures. Immunity, 2022, 55, 115-128.e9.	6.6	62
2	lgA-Dominated Humoral Immune Responses Govern Patients' Outcome in Endometrial Cancer. Cancer Research, 2022, 82, 859-871.	0.4	21
3	Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory TÂcells. Cancer Cell, 2022, 40, 545-557.e13.	7.7	53
4	Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors. Molecular Cancer Therapeutics, 2022, 21, 1184-1194.	1.9	12
5	Exposure to a mycovirus containing Aspergillus Flavus reproduces acute lymphoblastic leukemia cell surface and genetic markers in cells from patients in remission and not controls. Cancer Treatment and Research Communications, 2021, 26, 100279.	0.7	5
6	HDAC11 regulates expression of C/EBPβ and immunosuppressive molecules in myeloid-derived suppressor cells. Journal of Leukocyte Biology, 2021, 109, 891-900.	1.5	7
7	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Advances, 2021, 5, 2740-2750.	2.5	6
8	Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight, 2021, 6, .	2.3	8
9	Plasma of Acute Lymphoblastic Leukemia Patients React to the Culture of a Mycovirus Containing Aspergillus flavus. Journal of Pediatric Hematology/Oncology, 2020, 42, 350-358.	0.3	4
10	HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology, 2020, 11, 590072.	2.2	14
11	The dual PI3KÎ′/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances, 2020, 4, 3072-3084.	2.5	52
12	HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms. Blood, 2020, 135, 191-207.	0.6	40
13	Indian Buddhist concepts of normative and deviant bodies: can ancient sexual mores be reconciled with modern sensibilities?. Religion, 2019, 49, 735-744.	0.3	2
14	Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms. Blood, 2019, 134, 474-474.	0.6	1
15	Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia. Blood, 2019, 134, 3382-3382.	0.6	1
16	Abstract 4723: Combinatorial efficacy of anti-PD1 treatment and selective histone deacetylase 6 (HDAC6) inhibition in chronic lymphocytic leukemia (CLL). , 2019, , .		0
17	Abstract LB-074: Priming the tumor microenvironment with epigenetic modifiers to overcome resistance to immune checkpoint inhibitors. , 2019, , .		Ο
18	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplantation, 2018, 53, 1434-1444.	1.3	8

#	Article	IF	CITATIONS
19	Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia. Blood Advances, 2018, 2, 3012-3024.	2.5	16
20	A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease. Leukemia Research, 2018, 74, 89-96.	0.4	42
21	Abstract 1703: The HDAC6 inhibitor Nexturastat A improvesin vivoPD-1 immune blockade. , 2018, , .		0
22	Abstract 4967: HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition. , 2018, , .		0
23	Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment. Blood, 2018, 132, 1105-1105.	0.6	1
24	Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival. Blood, 2018, 132, 3223-3223.	0.6	1
25	T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood, 2017, 130, 146-155.	0.6	54
26	Essential role for histone deacetylase 11 (HDAC11) in neutrophil biology. Journal of Leukocyte Biology, 2017, 102, 475-486.	1.5	44
27	HDAC11 as a candidate therapeutic target in multiple myeloma Journal of Clinical Oncology, 2017, 35, 8029-8029.	0.8	1
28	Abstract 4055: Enhancing anti-PD-1 immune blockade in melanoma through selective inhibition of histone deacetylase 6. , 2017, , .		0
29	Expression and Function of Histone Deacetylase 10 (HDAC10) in B Cell Malignancies. Methods in Molecular Biology, 2016, 1436, 129-145.	0.4	7
30	Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia. Leukemia Research, 2016, 47, 78-83.	0.4	17
31	Functional Analysis of Histone Deacetylase 11 (HDAC11). Methods in Molecular Biology, 2016, 1436, 147-165.	0.4	8
32	Essential role of HDAC6 in the regulation of PD‣1 inÂmelanoma. Molecular Oncology, 2016, 10, 735-750.	2.1	125
33	Abstract 545: Differential regulation of human T-cells by TGR-1202, a novel PI3K \hat{l} inhibitor. , 2016, , .		9
34	A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease. Blood, 2016, 128, 1892-1892.	0.6	4
35	Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202. Blood, 2016, 128, 3236-3236.	0.6	3
36	Abstract 2331: HDAC6, new role as master regulator of PD-L1 and immune-related pathways. , 2016, , .		0

#	Article	IF	CITATIONS
37	Abstract 4485: Regulation of chronic lymphocytic leukemia (CLL) immunobiology by histone deacetylase 6 (HDAC6). , 2016, , .		Ο
38	Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model. Blood, 2016, 128, 2035-2035.	0.6	0
39	Targeting histone deacetylase 6 mediates a dual antiâ€melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Molecular Oncology, 2015, 9, 1447-1457.	2.1	111
40	<scp>WT</scp> 1 vaccination in <scp>AML</scp> and <scp>MDS</scp> : A pilot trial with synthetic analog peptides. American Journal of Hematology, 2015, 90, 602-607.	2.0	50
41	Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Molecular Immunology, 2015, 63, 579-585.	1.0	98
42	Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition. Blood, 2014, 124, 225-225.	0.6	1
43	Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 3311-3311.	0.6	11
44	Abstract 5537: Histone deacetylase 11 (HDAC11) regulates B cell lymphopoiesis and potentiates plasma cell survival in multiple myeloma. , 2014, , .		0
45	Abstract 4090: Inhibition of class I histone deacetylases promotes robust and durable enhancement of PDL1 expression in melanoma: Rationale for combination therapy. , 2014, , .		Ο
46	A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma. Blood, 2014, 124, 4715-4715.	0.6	0
47	Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition. Blood, 2014, 124, 5423-5423.	0.6	0
48	A Novel Role For Histone Deacetylase 11 (HDAC11) In Plasma Cell Differentation and Survival. Blood, 2013, 122, 1907-1907.	0.6	1
49	A Novel Role For Histone Deacetylase 11 (HDAC11) As a Regulator Of Neutrophil Function and Differentiation In Normal and Malignant Hematopoesis. Blood, 2013, 122, 2267-2267.	0.6	1
50	Abstract 692: Histone deacetylase 11 is an epigenetic regulator of CD8+ T-cell effector function and memory formation , 2013, , .		0
51	Histone Deacetylase 11 (HDAC11) Is a Novel Regulator In The Expansion Of MDSCs Via The Transcription Factor C/EBP-β. Blood, 2013, 122, 4887-4887.	0.6	Ο
52	Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice. Blood, 2012, 120, 1027-1038.	0.6	60
53	Combination of ACY1215, a Selective Histone Deacetylase 6 (HDAC6) Inhibitor with the Bruton Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Represents a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL). Blood, 2012, 120, 1660-1660.	0.6	5
54	Abstract 3555: Histone deacetylase 6 as a novel regulator of the immunogenicity and aggressiveness of melanoma. , 2012, , .		0

#	Article	IF	CITATIONS
55	Abstract 3554: The histone deacetylase inhibitor LBH589 augments anti-tumor immunity through direct effects on tumor and immune cells leading to impaired tumor progressionin vivo. , 2012, , .		0
56	Abstract 4260: Histone deacetylase 11 (HDAC11) as a novel therapeutic target in the regulation of myeloid-derived suppressor cell (MDSC). , 2012, , .		0
57	Novel Role of Histone Deacetylase 11 (HDAC11) in Hematopoiesis. Blood, 2012, 120, 4728-4728.	0.6	Ο
58	Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine. Blood, 2012, 120, 3828-3828.	0.6	0
59	Physical Interaction of Histone Deacetylase 6 (HDAC6) with STAT3 Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2012, 120, 829-829.	0.6	0
60	Histone Deacetylase 11 (HDAC11) Regulates Cytotoxic T-Cell Function and Memory Phenotype. Blood, 2012, 120, 840-840.	0.6	0
61	Gender and Virtue in Indian Buddhism. CrossCurrents, 2011, 61, 428-440.	0.0	1
62	A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leukemia and Lymphoma, 2011, 52, 668-679.	0.6	33
63	Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2′-deoxycytidine. Leukemia Research, 2011, 35, 1193-1199.	0.4	15
64	Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leukemia Research, 2011, 35, 394-404.	0.4	17
65	The Opposing Role of Histone Deacetylase 10 (HDAC10) and HDAC11 in Proliferation/Survival of Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 1363-1363.	0.6	1
66	Epigenetic Modulation of STAT3 by Histone Deacetylase 6 (HDAC6) Regulates IL-10 Gene Expression and Immune Tolerance Mediated by Antigen-Presenting Cells (APCs). Blood, 2011, 118, 519-519.	0.6	2
67	Abstract 5526: Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2'-deoxycytidine. , 2011, , .		0
68	Tubastatin A, a Selective HDAC6 Inhibitor, Enhances Antigen-Presenting Cell (APC) Function and Restores the Responsiveness of Anergic CD4+ T Cells. Blood, 2011, 118, 520-520.	0.6	0
69	Enhanced Immunological Responses Following K562/GM-CSF/CD40L Vaccine Plus Lenalidomide in High-Risk Myelodysplastic Syndrome. Blood, 2011, 118, 1725-1725.	0.6	1
70	A Novel Role of Histone Deacetylase 11 (HDAC11) in Regulation of Myeloid-Derived Suppressor Cell (MDSC) Expansion. Blood, 2011, 118, 2439-2439.	0.6	1
71	Circumventing Immune Tolerance Through Epigenetic Modification. Current Pharmaceutical Design, 2010, 16, 268-276.	0.9	11
72	Abstract 4771: Molecular, epigenetic, and phenotypic repolarization of human T lymphocytes using		0

5-aza-2â€²-deoxycytidine increases CD8 responsiveness and induces Th1 polarity. , 2010, , .

JOHN J POWERS

#	Article	IF	CITATIONS
73	Correlative Analysis of T Cell Subpopulations and CD20 Expression In a Phase II Study of Lenalidomide In Combination with Rituximab In Patients with Relapsed or Refractory CLL/SLL. Blood, 2010, 116, 4630-4630.	0.6	0
74	A Phase I Pilot Study of Bystander Vaccine and Lenalidomide Immune Augmentation In Patients with Myelodysplastic Syndrome (MDS). Blood, 2010, 116, 2925-2925.	0.6	1
75	Molecular, Epigenetic, and Phenotypic Repolarization of T Lymphocytes From Chronic Lymphocytic Leukemia Patients Using 5-Aza-2′-Deoxycytidine. Blood, 2010, 116, 4651-4651.	0.6	0
76	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen. Clinical Cancer Research, 2009, 15, 3406-3415.	3.2	38
77	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis Blood, 2009, 114, 2376-2376.	0.6	3
78	Hypercalcemia Following Treatment with Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Blood, 2009, 114, 4413-4413.	0.6	0
79	Molecular Profiling of Cancer Testis Antigens in Chronic Lymphocytic Leukemia Blood, 2009, 114, 4701-4701.	0.6	0
80	Restoring the Functional Immunogenicity of Chronic Lymphocytic Leukemia Using Epigenetic Modifiers Blood, 2009, 114, 5116-5116.	0.6	0
81	Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy Blood, 2009, 114, 2204-2204.	0.6	0
82	A Comprehensive Lymphocyte Analysis of Dasatinib Treated Chronic Myelogenous Leukemia Patients Reveals T-Cell Oligoclonality Blood, 2008, 112, 1114-1114.	0.6	2
83	Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, An Immunogenic Cancer Testis Antigen. Blood, 2008, 112, 4207-4207.	0.6	0
84	Changes in Immunogenicity of Chronic Lymphocytic Leukemia Cells Mediated by Epigenetic Modifiers. Blood, 2008, 112, 4202-4202.	0.6	28
85	The novel differentiation of human blood mononuclear cells into CD1a-negative dendritic cells is stimulated in the absence of exogenous cytokines by an extract prepared from pinecones. International Immunopharmacology, 2003, 3, 209-223.	1.7	10
86	Mothering: Moral Cultivation in Buddhist and Feminist Ethics. Philosophy East and West, 1994, 44, 1.	0.0	3